Modality
Nanobody
MOA
CAR-T BCMA
Target
PI3Kα
Pathway
Cell Cycle
TTR Amyloidosis
Development Pipeline
Preclinical
~Apr 2022
→ ~Jul 2023
Phase 1
~Oct 2023
→ ~Jan 2025
Phase 2
Apr 2025
Phase 2Current
NCT04704245
417 pts·TTR Amyloidosis
2025-04→TBD·Completed
417 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
Q2
P2
Complet…
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04704245 | Phase 2 | TTR Amyloidosis | Completed | 417 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn | |
| 369-789 | Hansoh Pharma | Phase 3 | PI3Kα | |
| Mavutuximab | Hansoh Pharma | Phase 2/3 | PI3Kα | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα |